News from the FDA/CDC

FDA approves injectable treatment for cheek lines, wrinkles


 

The Food and Drug Administration has approved injectable poly-L-lactic acid (PLLA-SCA) for the correction of fine lines and wrinkles in the cheek, the manufacturer announced on April 26.

The treatment, marketed as Sculptra, is the first FDA-approved PLLA collagen stimulator that, “when injected into the cheek area, helps stimulate natural collagen production to smooth wrinkles and improve skin quality such as firmness and glow,” according to a press release from the manufacturer, Galderma. Sculptra was first approved for aesthetic use in 2009 in the United States and is now available in more than 40 countries.

A stamp saying "FDA approved." Olivier Le Moal/Getty Images

With this expanded approval, PLLA-SCA is now indicated for use in people with healthy immune systems for correcting shallow to deep nasolabial fold contour deficiencies, fine lines, and wrinkles in the cheeks and other facial areas.

94% have enduring improvement at 2 years

In a clinical trial, PLLA-SCA achieved the primary efficacy endpoint of at least a 1-grade improvement in wrinkles on both cheeks concurrently at rest and its secondary endpoint of improving cheek wrinkles when smiling for up to 2 years, the company states.

According to Galderma, patients showed aesthetic improvement in cheek wrinkles throughout the study; 96% showed improvement at 3 months, 94% showed improvement at 1 year, and 94% showed improvement at 2 years.

The most common side effects after initial treatment are injection site swelling, tenderness, redness, pain, bruising, bleeding, itching, and lumps, according to the company. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area.

PLLA-SCA is available only through a licensed practitioner and should not be used by people allergic to any ingredient of the product or who have a history of keloid formation or hypertrophic scarring. The company notes that safety has not been established in patients who are pregnant, lactating, breastfeeding, or younger than 18.

In its instruction to clinicians, the company warns the treatment should not be injected into the blood vessels “as it may cause vascular occlusion, infarction, or embolic phenomena.”

Skin sores, cysts, pimples, rashes, hives, or infection should be healed completely before injecting the treatment, the company cautions. PLLA-SCA should not be injected into the red area of the lip or in the periorbital area.

A version of this article first appeared on Medscape.com.

Recommended Reading

Graying of hair: Could it be reversed?
Federal Practitioner
Hair regrowth stimulated by microneedle patch in preclinical study
Federal Practitioner
FDA issues warning about use of dermal fillers with needle-free devices
Federal Practitioner
FDA issues stronger safety requirements for breast implants
Federal Practitioner
FDA warns companies selling OTC skin lighteners
Federal Practitioner
Poor representation of patients with darker skin phototypes in laser and light device studies
Federal Practitioner
Ten-year analysis finds relatively low complication rate from fractional resurfacing lasers
Federal Practitioner
Small study finds IPL-radiofrequency combination effective for dry eye disease
Federal Practitioner
Branding tattoo removal helps sex trafficking survivor close door on painful past
Federal Practitioner
Could combining topical antioxidants with a nonablative laser prevent acne scars?
Federal Practitioner